Novo Nordisk (NVO) is recruiting a new head for its investor relations department: Michael Novod, a top healthcare equity ...

By Maggie Fick and Jacob Gronholt-Pedersen LONDON/COPENHAGEN (Reuters) -A boardroom shake-up at Novo Nordisk has handed ...

Novo Nordisk, which lobbied to win Medicaid reimbursement for its obesity drug Wegovy, is fighting to keep that coverage as ...

The chairman of Novo Nordisk and six other independent board members quit on Tuesday after a dispute with the company's ...

The changing of the guard at Novo Nordisk took another turn this week as the company revealed that seven members of its board ...

Shares of Novo Nordisk fell around 3% on Wednesday, extending their losses from a day earlier, after the Wegovy maker's top ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Novo Nordisk today announced new data on the investigational oral semaglutide 25 mg will be among 23 abstracts to be ...

Get the latest on Novo Nordisk's Alzheimer's trial, stock outlook, and market risks. See what investors need to know before ...

The maker of the popular weight-loss drug Wegovy announced on Wednesday that it will be cutting 9,000 jobs in the company. Novo Nordisk said a majority of the jobs lost, 5,000 of them, will be in ...

Another week, another twist in the turnaround efforts at Novo Nordisk, the maker of the blockbuster Ozempic and Wegovy weight ...

Discover how potential U.S. price cuts on obesity drugs could impact LLY and NVO revenues, stock sentiment, and valuation ...